ARTICLE | Clinical News
Salagen pilocarpine tablets: Phase III data; marketed
November 12, 2001 8:00 AM UTC
MOGN said that in a Phase III study of 244 head and neck cancer patients undergoing radiation therapy, Salagen gave a statistically significant improvement in salivary flow compared to placebo. The di...